Blockade of CD11a by Efalizumab in Psoriasis Patients Induces a Unique State of T-Cell Hyporesponsiveness

Efalizumab (anti-CD11a) interferes with LFA-1/ICAM-1 binding and inhibits several key steps in psoriasis pathogenesis. This study characterizes the effects of efalizumab on T-cell activation responses and expression of surface markers on human circulating psoriatic T cells during a therapeutic trial...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of investigative dermatology 2008-05, Vol.128 (5), p.1182-1191
Hauptverfasser: Guttman-Yassky, Emma, Vugmeyster, Yulia, Lowes, Michelle A., Chamian, Francesca, Kikuchi, Toyoko, Kagen, Mark, Gilleaudeau, Patricia, Lee, Edmund, Hunte, Brisdell, Howell, Kathy, Dummer, Wolfgang, Bodary, Sarah C., Krueger, James G.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!